Vitality Watch

Dossier clinicaltrials observational 30-jun-2026
Human cohort, case-control, or epidemiological association

Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?

Key claim: A prospective observational study will test whether serum lumican levels can identify a hidden fragility phenotype beyond bone mineral density in postmenopausal women.

Abstract

Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility. Lumican, an extracellular matrix proteoglycan involved in collagen organization and musculoskeletal tissue homeostasis, has emerged as a potential biomarker for bone health. This prospective observational study aims to investigate the relationship between serum lumican levels, bone mineral density, muscle strength, and clinical fragility indicators in postmenopausal women. Approximately 100 participants will undergo routine osteoporosis assessment including DEXA, laboratory testing, FRAX evaluation, and handgrip strength measurement. The study will evaluate whether serum lumican levels can identify a hidden fragility phenotype beyond conventional bone mineral density measurements.

Why this matters

A prospective observational study will test whether serum lumican levels can identify a hidden fragility phenotype beyond bone mineral density in postmenopausal women.

Source

Link

Briefing card

Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
Stage: observational · clinicaltrials · 30-jun-2026

A prospective observational study will test whether serum lumican levels can identify a hidden fragility phenotype beyond bone mineral density in postmenopausal women.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07677072

build build 880 · 2bcef25 · 2026-11-18